ストックスクリーナーアプリを入手
2.17
4.33%
0.09
アフターアワーズ：
2.17
前日終値:
$2.08
開ける：
$2.11
24時間の取引高:
30,186
Relative Volume:
0.13
時価総額：
$6.06M
収益：
-
当期純損益:
$-14.11M
株価収益率:
-0.2025
EPS:
-10.7181
ネットキャッシュフロー:
$-13.60M
1週間 パフォーマンス:
+1.88%
1か月 パフォーマンス:
-16.54%
6か月 パフォーマンス:
+11.86%
1年 パフォーマンス:
-60.18%
1日の値動き範囲:
$2.04
$2.18
1週間の範囲:
$2.00
$2.22
52週間の値動き範囲:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
名前
Processa Pharmaceuticals Inc
セクター
電話
443-776-3133
住所
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.17 | 5.99M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-25 | 開始されました | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc (PCSA) 最新ニュース
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsChaikin Flow - dars.gov.et
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com Nigeria
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into FocusPercent Above MA - vinanet.vn
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com UK
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) Surges 11.74% to $2.57 — Poised for a Test of $2.70 ResistanceQuality Factor - vinanet.vn
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
PCSA Stock Jumps As Traders Pile Into Biotech Micro-Cap - StocksToTrade
Processa Pharmaceuticals Inc - TradingKey
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) grants director 33,500 RSUs and reports option stake - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.080|Chg%:-0.065 - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.600|Chg%:-0.270 - TradingKey
PCSA Q4 2025 Earnings: Significant EPS Miss Highlights Ongoing Development CostsRevenue Growth Report - vinanet.vn
Processa Pharmaceuticals (PCSA) Shares Rise 3% as Support Holds Above $2.19Triple Bottom - vinanet.vn
PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline ProgressTax Rate Impact - dars.gov.et
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates, No Revenue ReportedOperating Margin Analysis - dars.gov.et
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com South Africa
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals Inc (PCSA) 財務データ
収益
当期純利益
現金流量
EPS
Processa Pharmaceuticals Inc (PCSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):